09.12.2010 22:13:08 Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker – a new market research report on companiesandmarkets.com
(live-PR.com) – Who are the players and products in the race to launch?
This report critically assesses the candidates in their wider market context, providing a complete review of the market and its likely development to 2013.
The launch of Sanofi Pasteur MSD´s Gardasil and GSK´s Cervarix has propelled cancer vaccines from research obscurity to a key area of commercial and clinical interest. But can the sector capitalise on these gains and really fulfill its promise?
By 2010, the global cancer market is expected to generate sales in excess of US$60 billion due to growth in the sales of existing innovative products and the launch of nearly 60 new products which will account for around 30% of total drug launches.
But where do cancer vaccines fit into this outlook? At present, prophylactic vaccines dominate the cancer vaccine sector following the recent launches of Sanofi Pasteur MSD´s Gardasil and GlaxoSmithKline´s Cervarix. We expect that sales of these vaccines will break through US$4 billion by 2011.
While there is no therapeutic vaccine market, so to speak of, at present, it has the potential to mirror the growth seen in the monoclonal antibody market, and reach sales in excess of US$5 billion by 2012. This prediction may be optimistic and is highly dependent on vaccines being approved for major cancer indications – no small challenge taking the development history of the sector.
While no new therapeutic cancer vaccine has been approved recently the product pipeline has changed substantially, shifting from one filled with vaccines at the Phase I and II stage, to a more mature pipeline reflecting a shift in development towards the later stages.
This is a consequence, not only of the age of the pipeline, but of the difficulties and pitfalls that therapeutic cancer vaccine development faces. Many vaccines have fallen by the wayside for one reason or another. Indeed the rush to join this area of research has waned slightly with the realisation that products are harder to bring to market than first anticipated.
Types of cancer vaccine:
Whole-cell tumour vaccines
Dendritic cell vaccines
Viral vectors and DNA vaccines
This report includes the CANCER VACCINE TRACKER
If you need to stay in touch with the latest developments in cancer vaccines, then you should use the unique online service Cancer Vaccine Tracker. Updated on an ongoing basis, the Tracker will keep you up-to-date with the very latest product, regulatory, company and research developments. Available to buyers of the online edition of this report.
Click for report details: www.companiesandmarkets.com/Market-Report/cancer ..